Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori

Helicobacter

Volumn 3, Issue 1, 1998, Pages 21-27

  Nakao, Masafumi ^a   Malfertheiner, Peter ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; GROWTH INHIBITOR; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; SULFOXIDE; UREASE;

ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER PYLORI; HUMAN; METABOLISM; SCANNING ELECTRON MICROSCOPY; ULTRASTRUCTURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; GROWTH INHIBITORS; HELICOBACTER PYLORI; HUMANS; MICROSCOPY, ELECTRON, SCANNING; OMEPRAZOLE; SULFOXIDES; UREASE;

EID: 0032010835     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5378.1998.08024.x     Document Type: Article

References (14)

1. Blaser MJ. Gastric Campylobacter-like organisms, gastritis and peptic ulcer disease. Gastroenterol 1987;93:371-83.
2. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow CR. Prospective, double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
3. Goodwin CS, Blake P, Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother 1986; 17:309-14.
4. McNulty CAM, Dent JC. Susceptibility of clinical isolates of Camplyobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis 1988;7:566-9.
5. Garcia-Rodriguez JA, Garcia-Sanchez JE, Garcia-Garcia MI, Garcia-Sanchez E, Munoz-Bellido JL. In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori. Antimicrob Agents Chemother 1989;33:1650-1.
6. Westblom TU, Gudipati S, Midkiff BR. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins, cefpodoxime, cefibuten and cefixime. Eur J Clin Microbiol Infect Dis 1990;9:691-3.
7. von Recklinghausen G, Mario CD, Ansorg R. Activity of antibiotics and azole antimycotics against Helicobacter pylori. Zentralbl Bakteriol 1993; 280:279-85.
8. Glupczynski Y. In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection. In: Malfertheiner P, Ditschuneit H, eds. Helicobacter pylori, Gastritis and Peptic Ulcer. Berlin: Springer-Verlag KG, 1990;49-58.
9. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-6.
10. Nakao M, Tada M, Tsuchimori K, Uekata M. Antibacterial properties of lansoprazole alone or in combination with antimicrobial agents against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1995;14:391-9.
11. Suerbaum S, Leying H, Klemm K, Opferkuch W. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991;10:93-4.
12. Witzel L, Gutz H, Huttemann W, Schepps W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995;9:19-24.
13. Penner JL. Campylobacter, Helicobacter and related spiral bacteria. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology, 1991; 402-9.
14. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 1993;328:349-50.